Cargando…

Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?

Interstitial lung disease (ILD) is a severe and frequent manifestation of connective tissue diseases (CTD). Due to its debilitating potential, it requires serious evaluation and treatment. The prevalence of ILD in systemic lupus erythematosus (SLE) is still controversial. Therefore, in order to esta...

Descripción completa

Detalles Bibliográficos
Autores principales: Richter, Patricia, Cardoneanu, Anca, Dima, Nicoleta, Bratoiu, Ioana, Rezus, Ciprian, Burlui, Alexandra Maria, Costin, Damiana, Macovei, Luana Andreea, Rezus, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253395/
https://www.ncbi.nlm.nih.gov/pubmed/37298342
http://dx.doi.org/10.3390/ijms24119388
_version_ 1785056395705450496
author Richter, Patricia
Cardoneanu, Anca
Dima, Nicoleta
Bratoiu, Ioana
Rezus, Ciprian
Burlui, Alexandra Maria
Costin, Damiana
Macovei, Luana Andreea
Rezus, Elena
author_facet Richter, Patricia
Cardoneanu, Anca
Dima, Nicoleta
Bratoiu, Ioana
Rezus, Ciprian
Burlui, Alexandra Maria
Costin, Damiana
Macovei, Luana Andreea
Rezus, Elena
author_sort Richter, Patricia
collection PubMed
description Interstitial lung disease (ILD) is a severe and frequent manifestation of connective tissue diseases (CTD). Due to its debilitating potential, it requires serious evaluation and treatment. The prevalence of ILD in systemic lupus erythematosus (SLE) is still controversial. Therefore, in order to establish the diagnosis of ILD, an overlap syndrome must be excluded. Increasing the identification of SLE-associated ILD cases should become a target. To treat this complication, various therapies are now being proposed. To date, no placebo-controlled studies were conducted. Regarding another CTD, systemic sclerosis (SSc), SSc-associated ILD is considered one of the leading causes of mortality. The incidence of ILD varies among disease subtypes, being influenced by diagnostic method, but also by disease duration. Due to the high prevalence of this complication, all SSc patients should be investigated for ILD at the time of SSc diagnosis and during the course of the disease. Fortunately, progress was made in terms of treatment. Nintedanib, a tyrosine kinases inhibitor, showed promising results. It appeared to decrease the rate of progression of ILD compared to placebo. This review aimed to provide up-to-date findings related to SLE-associated ILD and SSc-associated ILD, in order to raise awareness of their diagnosis and management.
format Online
Article
Text
id pubmed-10253395
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102533952023-06-10 Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge? Richter, Patricia Cardoneanu, Anca Dima, Nicoleta Bratoiu, Ioana Rezus, Ciprian Burlui, Alexandra Maria Costin, Damiana Macovei, Luana Andreea Rezus, Elena Int J Mol Sci Review Interstitial lung disease (ILD) is a severe and frequent manifestation of connective tissue diseases (CTD). Due to its debilitating potential, it requires serious evaluation and treatment. The prevalence of ILD in systemic lupus erythematosus (SLE) is still controversial. Therefore, in order to establish the diagnosis of ILD, an overlap syndrome must be excluded. Increasing the identification of SLE-associated ILD cases should become a target. To treat this complication, various therapies are now being proposed. To date, no placebo-controlled studies were conducted. Regarding another CTD, systemic sclerosis (SSc), SSc-associated ILD is considered one of the leading causes of mortality. The incidence of ILD varies among disease subtypes, being influenced by diagnostic method, but also by disease duration. Due to the high prevalence of this complication, all SSc patients should be investigated for ILD at the time of SSc diagnosis and during the course of the disease. Fortunately, progress was made in terms of treatment. Nintedanib, a tyrosine kinases inhibitor, showed promising results. It appeared to decrease the rate of progression of ILD compared to placebo. This review aimed to provide up-to-date findings related to SLE-associated ILD and SSc-associated ILD, in order to raise awareness of their diagnosis and management. MDPI 2023-05-28 /pmc/articles/PMC10253395/ /pubmed/37298342 http://dx.doi.org/10.3390/ijms24119388 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Richter, Patricia
Cardoneanu, Anca
Dima, Nicoleta
Bratoiu, Ioana
Rezus, Ciprian
Burlui, Alexandra Maria
Costin, Damiana
Macovei, Luana Andreea
Rezus, Elena
Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?
title Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?
title_full Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?
title_fullStr Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?
title_full_unstemmed Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?
title_short Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?
title_sort interstitial lung disease in systemic lupus erythematosus and systemic sclerosis: how can we manage the challenge?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253395/
https://www.ncbi.nlm.nih.gov/pubmed/37298342
http://dx.doi.org/10.3390/ijms24119388
work_keys_str_mv AT richterpatricia interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge
AT cardoneanuanca interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge
AT dimanicoleta interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge
AT bratoiuioana interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge
AT rezusciprian interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge
AT burluialexandramaria interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge
AT costindamiana interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge
AT macoveiluanaandreea interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge
AT rezuselena interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge